In a significant move to bolster its pipeline and solidify its strategic focus on the complex challenges of obesity, global…
Read More
Daiichi Sankyo Partners with Waiv to Accelerate Digital Pathology Biomarker Discovery for Antibody-Drug Conjugate Programs
In a strategic move to enhance precision in oncology drug development, Japanese pharmaceutical giant Daiichi Sankyo has announced a significant…
Read More
Citius Oncology Secures Up to $36.5 Million in Debt and Equity Financing to Fuel Lymphir Commercialization
Citius Oncology has successfully secured a significant financial infusion, totaling up to $36.5 million, through a strategic combination of debt…
Read More
Navigating the Evolving Landscape of Oral Solid Dosage Development: A Framework for Enhanced Efficiency and Commercial Success
The pharmaceutical industry is witnessing a significant evolution in oral solid dosage (OSD) development, driven by an increasing demand for…
Read More
Bayer Acquires Perfuse Therapeutics for Up to $2.45 Billion to Bolster Ophthalmology Pipeline with Novel Endothelin Receptor Antagonist
Bayer AG is set to significantly expand its presence in the ophthalmology market with the acquisition of Perfuse Therapeutics, a…
Read More
Merck & Co. Acquires Terns Pharmaceuticals, Bolstering Chronic Myeloid Leukemia Pipeline with FDA Breakthrough Designation for TERN-701
Merck & Co. (MSD) has successfully completed its acquisition of Terns Pharmaceuticals, a strategic move that significantly enhances MSD’s portfolio…
Read More
FDA Approves Langlara, an Interchangeable Biosimilar for Diabetes Management, Expanding Patient Access and Treatment Options
Sunshine Lake Pharma, Lannett Company, and its wholly owned subsidiary Lanexa Biologics have achieved a significant milestone in diabetes care…
Read More
The Shifting Landscape of Gene Therapy: Non-Viral Approaches Emerge as Promising Alternatives
Cell and gene therapies (CGTs) have long been heralded for their potential to revolutionize the treatment of complex and previously…
Read More
Madrigal Pharmaceuticals Secures Global Rights to Arrowhead’s siRNA Asset for MASH, Paving Way for Combination Therapy Exploration
Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion to Bolster Autoimmune Disease Pipeline with Novel T-Cell Engagers
UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read More
